12:00 AM
Jun 10, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Avastin bevacizumab: Phase III final data

Avastin has accelerated approval in the U.S. and is approved in over 30 countries worldwide to treat glioblastoma in patients with progressive disease following prior therapy. Genentech said it conducted AVAglio as part of a postmarketing commitment to FDA for Avastin in glioblastoma. Genentech said it will discuss the data with regulatory authorities, but declined to comment as to whether an OS benefit for Avastin is needed to be shown for full approval, or if a PFS benefit is sufficient.

Avastin is approved in the EU and U.S. for...

Read the full 428 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >